Loading...
•
Mar 31
ADMA Biologics Q1 2025 Earnings Report
ADMA Biologics announced its first quarter 2025 financial results, highlighting significant year-over-year growth in revenue, net income, and adjusted EBITDA.
Key Takeaways
ADMA Biologics reported a strong start to 2025 with total revenue increasing 40% year-over-year to $114.8 million and GAAP Net Income rising 51% to $26.9 million. Adjusted EBITDA saw an 81% increase to $47.9 million. The company also highlighted the FDA approval of its yield enhancement process and increased its full-year 2025 and 2026 guidance, alongside authorizing a $500 million share repurchase program.
Strong Q1 2025 financial performance with significant year-over-year growth in revenue, net income, and adjusted EBITDA.
FDA approval of the yield enhancement process expected to boost production output by 20% and support future growth and margin expansion.
Increased full-year 2025 and 2026 financial guidance across key metrics, including revenue, adjusted net income, and adjusted EBITDA.
Authorization of a $500 million share repurchase program and strengthened balance sheet position with approximately $171 million in cash and receivables.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA Biologics increased its full-year 2025 and 2026 revenue and Adjusted EBITDA guidance and reaffirmed/increased Adjusted Net Income guidance, projecting significant growth through 2030.
Positive Outlook
- FY 2025 Total Revenue guidance increased to more than $500 million.
- FY 2026 Total Revenue guidance increased to more than $625 million.
- FY 2025 Adjusted Net Income guidance reiterated to be $175 million or more.
- FY 2026 Adjusted Net Income guidance increased to $245 million or more.
- FY 2025 Adjusted EBITDA guidance increased to more than $235 million.
- FY 2026 Adjusted EBITDA guidance increased to more than $340 million.
- Pre-2030 total annual revenue guidance increased to $1.1 billion or more.
- Potential SG-001 annual revenue of $300-$500 million or more.
- Anticipated outsized earnings growth from current margin levels.